UK’s newest Lighthouse Lab boosts the country’s COVID-19 testing capacity, while generating hundreds of new local jobs WALTHAM, Mass. – November 30, 2020 – PerkinElmer, Inc., announced today the Lighthouse Lab in Charnwood, Loughborough, England is now processing COVID-19 testing samples as part of the Company’s collaboration with the Department of Health and Social... Read more
Lactoscope™ FT-B instrument provides accurate, cloud-connected testing and results in under 45 seconds WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the LactoScope™ FT-B instrument, which delivers quick and accurate full spectrum component testing and adulterant screening for liquid dairy products such as whey, raw and skim milk, shelf... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Michel Vounatsos has been elected to its board of directors, effective March 1, 2020. “I am excited to welcome Michel to PerkinElmer’s board, as he brings us deep knowledge and broad-based experience in key end markets,”... Read more
Spectrum Two™ FT-IR spectrometer and software part of scientific collaboration with eXXpedition WALTHAM, Mass. – November 14, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced its Spectrum Two™ FT-IR spectrometer solution is onboard a research trip led by eXXpedition, a not-for-profit organization running all-women sailing voyages investigating ocean... Read more
New LPC 500-Avio 500 ICP-OES Oils solution streamlines workflows and delivers accurate results in under 60 seconds WHAT: PerkinElmer Inc. has today announced its new LPC 500™ Liquid Particle Counter (LPC 500) platform which will couple with PerkinElmer’s existing Avio® 500 ICP-OES Oils system to join, for the first time, particle counting and sizing as well... Read more
WALTHAM, Mass.–(BUSINESS WIRE)–Sep. 13, 2019– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it is giving notice of the redemption of all of its outstanding 5% Senior Unsecured Notes due in 2021 (the “2021 Notes”). In accordance with the terms of the indenture governing the 2021... Read more
WALTHAM, Mass.–(BUSINESS WIRE)–Sep. 10, 2019– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $850 million aggregate principal amount of 3.300% Senior Notes due 2029 at an issue price of 99.670% of the principal amount. The issuance of the notes is... Read more
CE-Marked Solution Gives Pregnant Women Widespread Access to Non-Invasive Prenatal Testing WALTHAM, Mass. – August 21, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its Vanadis® fully automated non-invasive prenatal testing (NIPT) system has been validated in an external clinical study, titled “Clinical Validation of a... Read more
New assay provides in vitro determination of galactomannoprotein in immunocompromised patients WALTHAM, Mass. – August 5, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of the new EUROIMMUN Aspergillus Antigen ELISA.* The enzyme-linked immunosorbent assay is specifically designed to detect the Aspergillus antigen galactomannoprotein and... Read more
Combines PerkinElmer’s expertise in immunodiagnostic testing and state-of-the-art genomics program with EverlyWell’s consumer health offerings WALTHAM, Massachusetts, and AUSTIN, Texas – July 24, 2019 – Today, PerkinElmer, Inc. and EverlyWell, Inc. announced a new collaboration designed to accelerate innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer’s CLIA-certified and CAP-accredited lab facilities to... Read more